Literature DB >> 10364477

The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries.

X Ye1, K Fukudome, N Tsuneyoshi, T Satoh, O Tokunaga, K Sugawara, H Mizokami, M Kimoto.   

Abstract

Plasma protein C functions as an anticoagulant when it is converted to the active form of serine protease. Protein C activation has been found to be mediated by the endothelial cell surface thrombin/thrombomodulin (TM) complex. In addition, we recently identified the endothelial cell protein C/activated protein C receptor (EPCR) which is capable of high-affinity binding for protein C. In this study, we established monoclonal antibodies (mAbs) against EPCR including several function blocking antibodies. Immunohistochemical analysis using these mAbs demonstrated that EPCR is widely expressed in the endothelial cells of arteries, veins, and capillaries in the lung, heart, and skin. Function blocking anti-EPCR mAbs strongly inhibited protein C activation mediated by primary cultured arterial endothelial cells which express abundant EPCR. Anti-EPCR mAbs also prevent protein C activation mediated by microvascular endothelial cells. These results indicate that EPCR functions as an important regulator for the protein C pathway in various types of vessels. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364477     DOI: 10.1006/bbrc.1999.0846

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.

Authors:  András Gruber; Ulla M Marzec; Leslie Bush; Enrico Di Cera; José A Fernández; Michelle A Berny; Erik I Tucker; Owen J T McCarty; John H Griffin; Stephen R Hanson
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 2.  Endothelial cell protein C receptor: a multiliganded and multifunctional receptor.

Authors:  L Vijaya Mohan Rao; Charles T Esmon; Usha R Pendurthi
Journal:  Blood       Date:  2014-07-21       Impact factor: 22.113

3.  An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Patricia M Averell; Thomas J Cramer; Darlene J Elias; John H Griffin; Laurent O Mosnier
Journal:  Blood Adv       Date:  2020-08-11

4.  Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.

Authors:  Shiva Keshava; Jagan Sundaram; Anuradha Rajulapati; Charles Esmon; Usha Pendurthi; L Vijaya Mohan Rao
Journal:  Blood Adv       Date:  2017-06-27

5.  Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion.

Authors:  Jingying Wang; Ji Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

6.  Protein C system defects inflicted by the malaria parasite protein PfEMP1 can be overcome by a soluble EPCR variant.

Authors:  Jens E V Petersen; Eveline A M Bouwens; Ibai Tamayo; Louise Turner; Christian W Wang; Monique Stins; Thor G Theander; José Hermida; Laurent O Mosnier; Thomas Lavstsen
Journal:  Thromb Haemost       Date:  2015-07-09       Impact factor: 5.249

7.  Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis.

Authors:  Peter M Izmirly; Laura Barisoni; Jill P Buyon; Mimi Y Kim; Tania L Rivera; Julie S Schwartzman; Joseph M Weisstuch; David T Liu; Stephen Bernstein; Chung-E Tseng; Howard M Belmont; Charles T Esmon; Joan T Merrill; Anca D Askanase; David B Thomas; Robert M Clancy
Journal:  Rheumatology (Oxford)       Date:  2009-03-13       Impact factor: 7.580

8.  Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Authors:  Zhihui Zhong; Hristelina Ilieva; Lee Hallagan; Robert Bell; Itender Singh; Nicole Paquette; Meenakshisundaram Thiyagarajan; Rashid Deane; Jose A Fernandez; Steven Lane; Anna B Zlokovic; Todd Liu; John H Griffin; Nienwen Chow; Francis J Castellino; Konstantin Stojanovic; Don W Cleveland; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

9.  Coagulation factor Xa cleaves protease-activated receptor-1 and mediates signaling dependent on binding to the endothelial protein C receptor.

Authors:  R A Schuepbach; M Riewald
Journal:  J Thromb Haemost       Date:  2009-11-06       Impact factor: 5.824

10.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.